Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Magnetic Resonance Spectroscopy Studies of Cardiac Muscle Metabolism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Johns Hopkins University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00181259
First received: September 13, 2005
Last updated: June 15, 2010
Last verified: May 2008
  Purpose

The metabolism of the heart provides the chemical energy needed to fuel ongoing normal heart contraction. Magnetic resonance spectroscopy is a technique used in a MRI scanner that can be used to measure and study heart metabolism directly but without blood sampling or obtaining tissue biopsies. One of the hypotheses this study aims to investigate is whether energy metabolism is reduced in heart failure and whether that contributes to the poor heart function.


Condition
Heart Failure, Congestive

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: In Vivo Cardiac Metabolism in Normal, Ischemic, and Cardiomyopathic Patients

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Estimated Enrollment: 500
Study Start Date: January 1988
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Detailed Description:

This study uses MR spectroscopy to study heart metabolism and function in normal subjects and patients with left ventricular hypertrophy, dilated cardiomyopathy, and those with coronary artery disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients with coronary artery disease, dilated cardiomyopathy, or left ventricular hypertrophy

Criteria

Inclusion Criteria:

  • age > 18 years
  • Healthy subjects: no history of heart disease
  • Dilated cardiomyopathy: history of heart failure, EF<40%
  • Left ventricular hypertrophy: wall thickness >1.2cm
  • Coronary artery disease: >50% coronary lesion or positive stress test

Exclusion Criteria:

  • contraindication to MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00181259

Contacts
Contact: Robert G. Weiss, MD 410-955-1703 rweiss@jhmi.edu

Locations
United States, Maryland
Johns Hopkins Medical Institutions Recruiting
Baltimore, Maryland, United States, 21205
Contact: Tricia Steinberg, RN    443-287-3469    asteinb3@jhmi.edu   
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Robert G. Weiss, MD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Robert G. Weiss, M.D., Johns Hopkins University School of Medicine
ClinicalTrials.gov Identifier: NCT00181259     History of Changes
Other Study ID Numbers: JHU Cardiac MRS 88
Study First Received: September 13, 2005
Last Updated: June 15, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on November 19, 2014